- Conditions
- Multiple Myeloma, Bone Marrow Transplant Complications
- Interventions
- Autologous hematopoietic cell transplant
- Procedure
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 166
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- bortezomib, cyclophosphamide, dexamethasone
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Lenalidomide, dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Lenalidomide, Acetaminophen, Diphenhydramine, Montelukast, Carfilzomib, Daratumumab, Autologous Stem Cell Transplant (ASCT)
- Drug · Biological
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 7
- States / cities
- Miami, Florida • Tampa, Florida • Buffalo, New York + 4 more
- Conditions
- Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
- Interventions
- Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
- Drug
- Lead sponsor
- US Oncology Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- MILs, Melphalan, PCV13
- Biological · Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
- Drug · Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 70 more
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 19
- States / cities
- San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib, Placebo, Dexamethasone, Lenalidomide
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more
- Conditions
- Multiple Myeloma
- Interventions
- bb2121, Fludarabine, Cyclophosphamide, Lenalidomide
- Biological · Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Cyclophosphamide, Revlimid
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- Weight Lifting Exercises
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Multiple Myeloma
- Interventions
- Bendamustine, Carfilzomib, Dexamethasone
- Drug
- Lead sponsor
- Suzanne Lentzsch, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- alemtuzumab, methylprednisolone, prednisone, flow cytometry, immunologic technique, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib, Daratumumab - 16mg/kg, Bortezomib (BTZ), Daratumumab- 1800mg
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 58
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Atlanta, Georgia + 24 more
- Conditions
- Multiple Myeloma
- Interventions
- Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance, AHCT intensification, Dara-R consolidation, Dara-R maintenance, Dara-VRd induction
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Denver, Colorado • New York, New York + 7 more
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Interventions
- Ramantamig, Daratumumab, Pomalidomide, Lenalidomide, JNJ-102299639
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Atlanta, Georgia
- Conditions
- Multiple Myeloma
- Interventions
- TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more
- Conditions
- Refractory Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Syngeneic Bone Marrow Transplantation, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Filgrastim-sndz, Melphalan Hydrochloride
- Procedure · Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Etentamig, Lenalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 680 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2042
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more
- Conditions
- Multiple Myeloma
- Interventions
- venetoclax, lenalidomide, dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 7
- States / cities
- Duarte, California • Greenbrae, California • Los Angeles, California + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Ixazomib, Melphalan, Prednisone
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Morgantown, West Virginia